Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Emerging Trends in Quality Assurance for Life Sciences

Aug 11, 2025

Introduction to Emerging Trends in Quality Assurance

As the life sciences industry continues to evolve rapidly, the importance of quality assurance (QA) becomes increasingly paramount. This sector, encompassing pharmaceuticals, biotechnology, and medical devices, is under constant pressure to innovate while ensuring safety and efficacy. Emerging trends in QA are reshaping how companies maintain standards and comply with regulations, ultimately enhancing product quality and consumer trust.

quality assurance

Automation and Digital Transformation

One of the most significant trends in quality assurance is the adoption of automation and digital technologies. Automated systems streamline QA processes, reducing human error and increasing efficiency. Digital tools like artificial intelligence (AI) and machine learning (ML) are being harnessed to analyze large datasets, predict potential quality issues, and recommend solutions.

Moreover, digital transformation enables real-time monitoring of production processes, ensuring that any deviation from quality standards is immediately detected and addressed. This proactive approach not only saves time but also reduces costs associated with product recalls and non-compliance penalties.

Risk-Based Quality Management

Another key trend is the shift towards risk-based quality management. This approach involves prioritizing QA efforts based on the level of risk associated with different processes and products. By focusing on high-risk areas, companies can allocate resources more effectively and ensure that critical quality issues are addressed promptly.

risk management

Risk-based management also aligns with regulatory expectations, as authorities like the FDA encourage companies to adopt a risk-based mindset in their quality systems. This not only aids in compliance but also enhances overall product safety and effectiveness.

Integration of Quality by Design (QbD)

Quality by Design (QbD) is becoming an integral part of QA strategies in the life sciences industry. QbD involves designing products and processes with quality in mind from the outset, rather than relying solely on end-product testing. This proactive approach ensures that quality is built into products at every stage of the development process.

The implementation of QbD principles helps to identify potential quality issues early, reducing the likelihood of costly revisions or recalls. It also enhances regulatory compliance, as many global health authorities advocate for QbD methodologies.

quality design

Emphasis on Data Integrity

With the rise of digital tools and automation, ensuring data integrity has become a focal point in QA practices. Data integrity refers to the accuracy and reliability of data throughout its lifecycle. Inaccurate or compromised data can lead to incorrect conclusions and decisions, posing significant risks to product quality and safety.

To address this, companies are implementing stringent data governance policies and employing advanced data analytics tools to monitor data integrity continuously. These measures not only safeguard product quality but also enhance transparency and traceability in production processes.

Conclusion

The landscape of quality assurance in the life sciences industry is evolving rapidly, driven by technological advancements and changing regulatory requirements. By embracing emerging trends such as automation, risk-based management, Quality by Design, and a focus on data integrity, companies can ensure they remain competitive while delivering safe and effective products. As these trends continue to develop, they will play a crucial role in shaping the future of quality assurance in life sciences.